Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (141-150 of 211) with videos related to

Pageof 22
Sort By:
Cancer Research|September 5, 2002
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentBoris Lin, Klaus Podar, Deepak Gupta, et al.
Gastroenterology|May 13, 2023
Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal AdenocarcinomaSubodh Kumar, Jiangning Zhao, Srikanth Talluri, et al.
Experimental Hematology|December 3, 2014
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatmentGang An, Chirag Acharya, Shuhui Deng, et al.
Cancers|July 2, 2021
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple MyelomaYanira Ruiz-Heredia, Alejandra Ortiz-Ruiz, Mehmet K Samur, et al.
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Blood|February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cellsYu-Tzu Tai, Ender Soydan, Weihua Song, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Science Advances|June 5, 2021
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironmentJiye Liu, Teru Hideshima, Lijie Xing, et al.
Blood Cancer Discovery|September 27, 2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activationAnnamaria Gulla, Eugenio Morelli, Mehmet K Samur, et al.
Blood Advances|August 3, 2021
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyPeter G Miller, Adam S Sperling, Elliott J Brea, et al.
Pageof 22

Showing results (141-150 of 211) with videos related to

Sort By:
Pageof 22
Cancer Research|September 5, 2002
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentBoris Lin, Klaus Podar, Deepak Gupta, et al.
Gastroenterology|May 13, 2023
Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal AdenocarcinomaSubodh Kumar, Jiangning Zhao, Srikanth Talluri, et al.
Experimental Hematology|December 3, 2014
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatmentGang An, Chirag Acharya, Shuhui Deng, et al.
Cancers|July 2, 2021
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple MyelomaYanira Ruiz-Heredia, Alejandra Ortiz-Ruiz, Mehmet K Samur, et al.
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Blood|February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cellsYu-Tzu Tai, Ender Soydan, Weihua Song, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Science Advances|June 5, 2021
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironmentJiye Liu, Teru Hideshima, Lijie Xing, et al.
Blood Cancer Discovery|September 27, 2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activationAnnamaria Gulla, Eugenio Morelli, Mehmet K Samur, et al.
Blood Advances|August 3, 2021
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyPeter G Miller, Adam S Sperling, Elliott J Brea, et al.
Pageof 22